October 2, 2018 / 11:27 AM / 2 months ago

BRIEF-Go Therapeutics Enters Into Agreement With Roche For Glycotargeting Bispecific Cancer Treatment

Oct 2 (Reuters) - Roche Holding AG:

* GO THERAPEUTICS ENTERS INTO A LICENSE AGREEMENT WITH ROCHE FOR NEW GLYCOTARGETING BISPECIFIC CANCER TREATMENT

* GO THERAPEUTICS SAYS ROCHE WILL PAY CO UPFRONT AND NEAR-TERM MILESTONES OF $9 MILLION

* GO THERAPEUTICS-WILL BE ELIGIBLE TO RECEIVE UPTO $186 MILLION IN PAYMENTS WITH MID-SINGLE-DIGIT TO LOW DOUBLE-DIGIT ROYALTIES ON FUTURE PRODUCT SALES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below